Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs) Abstract #2940

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.
Aim(s): To investigate the efficacy of Avelumab, an anti-PD-L1 monoclonal antibody, in poorly differentiated, G3 NECs.
Materials and methods: The NET001 study (NCT03278405) is a single center, phase IIA study of Avelumab, (10mg/kg/IV every 2 weeks for a period of 52 weeks) in pts with poorly differentiated, WHO 2010 G3 NECs, from a gastrointestinal (GI) or lung source, who have progressed on a maximum of 2 lines of prior therapy.. The primary endpoint was ORR by RECIST v1.1; secondary endpoints included mPFS, mOS, DCR at 6 months, and toxicity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Victor Rodriguez-Freixinos

To read results and conclusion, please login ...

Further abstracts you may be interested in

#920 High Grade (G3) Neuroendocrine Neoplasms Should Be Further Classified According to Morphological Differentiation
Introduction: Neuroendocrine neoplasms (NENs) with a Ki-67 >20% (Grade 3) are classified together as Neuroendocrine Carcinomas (NEC), and are usually considered as poorly differentiated. However Grade (G)3 NENs may be heterogeneous, with some demonstrating a well-differentiated cell morphology.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: ...none of the below
Presenting Author: Dr Dalvinder Mandair
Keywords: Ki-67, g3 NENs
#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors
Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: PD Dr. Patricia Grabowski
#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?
Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Dalvinder Mandair
Authors: Furnace M, Muller G, Rundell C, Shah R, ...
#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)
Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: PD. Dr. Christian Fottner
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET